Physician and Patient Characteristics Associated With More Intensive End-of-Life Care.

Advanced cancer biomedical ethics chemotherapy emergency department end of life health care utilization hospitalization palliative care patient treatment preferences physician attitudes

Journal

Journal of pain and symptom management
ISSN: 1873-6513
Titre abrégé: J Pain Symptom Manage
Pays: United States
ID NLM: 8605836

Informations de publication

Date de publication:
08 2019
Historique:
received: 30 01 2019
revised: 12 04 2019
accepted: 12 04 2019
pubmed: 21 4 2019
medline: 17 9 2020
entrez: 21 4 2019
Statut: ppublish

Résumé

Although patient and physician characteristics are thought to be predictive of discretionary interventions at the end of life (EoL), few studies have data on both parties. To test the hypothesis that patient preferences and physician attitudes are both independently associated with discretionary interventions at the EoL. We report secondary analyses of data collected prospectively from physicians (n = 38) and patients with advanced cancer (n = 265) in the Values and Options in Cancer Care study. Predictor variables were patient attitudes toward EoL care and physician-reported comfort with medical paternalism, assessed indirectly using a modified version of the Control Preference Scale. We explored whether the magnitude of the physician variable was influenced by the inclusion of particular patient treatment-preference variables (i.e., effect modification). Outcomes were a chemotherapy use score (≤14 days before death [scored 2], 15-31 days before death [scored 1], and >31 days [scored 0]) and an emergency department visit/inpatient admission score (two or more admissions in the last 31 days [scored 2], one admission [1], and 0 admissions [0]) in the last month of life. Chemotherapy scores were nearly 0.25 points higher if patients expressed a preference for experimental treatments with unknown benefit at study entry (0.238 points, 95% CI = 0.047-0.429) or reported an unfavorable attitude toward palliative care (0.247 points, 95% CI = 0.047-0.450). A two-standard deviation difference in physician comfort with medical paternalism corresponded to standardized effects of 0.35 (95% CI = 0.03-0.66) for chemotherapy and 0.33 (95% CI = 0.04-0.61) for emergency department visits/inpatient admissions. There was no evidence of effect modification. Patient treatment preferences and physician attitudes are independently associated with higher levels of treatment intensity before death. Greater research, clinical, and policy attention to patient treatment preferences and physician comfort with medical paternalism might lead to improvements in care of patients with advanced disease.

Identifiants

pubmed: 31004774
pii: S0885-3924(19)30182-4
doi: 10.1016/j.jpainsymman.2019.04.014
pmc: PMC6679778
mid: NIHMS1529413
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

208-215.e1

Subventions

Organisme : NCI NIH HHS
ID : R01 CA140419
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197730
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM104940
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA168387
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG056589
Pays : United States

Informations de copyright

Copyright © 2019 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Références

JAMA. 2001 Dec 19;286(23):3007-14
pubmed: 11743845
JAMA. 2013 Feb 6;309(5):470-7
pubmed: 23385273
Am J Geriatr Psychiatry. 2016 Apr;24(4):261-71
pubmed: 26976293
Oncologist. 2016 Sep;21(9):1149-55
pubmed: 27412394
Can J Nurs Res. 1997 Fall;29(3):21-43
pubmed: 9505581
J Support Oncol. 2012 Jan-Feb;10(1):25-8
pubmed: 22005216
JAMA Oncol. 2015 Sep;1(6):778-84
pubmed: 26203912
N Engl J Med. 2011 Sep 29;365(13):1212-21
pubmed: 21991894
J Palliat Med. 2010 Jul;13(7):807-13
pubmed: 20636149
JAMA. 2012 Mar 7;307(9):915-6
pubmed: 22396510
Health Aff (Millwood). 2014 Jun;33(6):957-63
pubmed: 24889944
Health Aff (Millwood). 2018 Jan;37(1):95-103
pubmed: 29309227
Appl Health Econ Health Policy. 2015 Feb;13(1):1-6
pubmed: 25193241
Med Care. 1998 Feb;36(2):180-9
pubmed: 9475472
J Gen Intern Med. 2014 Jun;29(6):836-43
pubmed: 24449032
N Engl J Med. 1968 Jul 25;279(4):190-5
pubmed: 5658681
J Oncol Pract. 2016 Oct;12(10):e901-e911
pubmed: 27601514
Soc Sci Med. 2006 Jan;62(1):116-24
pubmed: 15992980
Med Care. 2009 Aug;47(8):835-41
pubmed: 19584765
N Engl J Med. 2015 Feb 12;372(7):678-82
pubmed: 25671263
Soc Sci Med. 1997 Dec;45(11):1715-27
pubmed: 9428090
JAMA. 2016 Jul 5;316(1):51-62
pubmed: 27380343
Intensive Care Med. 2012 Oct;38(10):1607-15
pubmed: 22885651
JAMA. 2011 Dec 28;306(24):2694-703
pubmed: 22203538
Am J Hosp Palliat Care. 2019 Mar;36(3):200-206
pubmed: 30079753
Soc Sci Med. 2004 Mar;58(5):939-53
pubmed: 14732607
Oncologist. 2009 Dec;14(12):1232-41
pubmed: 20007642
J Clin Oncol. 2012 Feb 1;30(4):394-400
pubmed: 22203758
Am J Bioeth. 2013;13(8):29-39
pubmed: 23862598
Intensive Care Med. 2013 Jun;39(6):1128-32
pubmed: 23435951
Patient Educ Couns. 2018 Jan;101(1):113-118
pubmed: 28716485
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Med Care. 2009 Oct;47(10):1098-105
pubmed: 19820614
CMAJ. 2017 Apr 3;189(13):E484-E493
pubmed: 28385893
J R Soc Med. 1994;87 Suppl 22:22-4; discussion 24-5
pubmed: 8064755
Psychooncology. 2015 Dec;24(12):1731-7
pubmed: 25959002
Cancer. 2010 Oct 1;116(19):4656-63
pubmed: 20572030
JAMA. 2016 Jan 19;315(3):284-92
pubmed: 26784776
Pers Soc Psychol Rev. 2010 May;14(2):155-95
pubmed: 20097885
Am Econ J Econ Policy. 2019 Feb;11(1):192-221
pubmed: 32843911
Patient Educ Couns. 2016 Mar;99(3):356-363
pubmed: 26519993
JAMA. 2009 Mar 18;301(11):1140-7
pubmed: 19293414
JAMA. 2008 Jun 18;299(23):2789-91
pubmed: 18560006
JAMA Oncol. 2017 Jan 01;3(1):92-100
pubmed: 27612178
Milbank Q. 2017 Mar;95(1):70-116
pubmed: 28266067
N Engl J Med. 2007 Feb 1;356(5):469-78
pubmed: 17267907
JAMA. 1999 Feb 3;281(5):446-53
pubmed: 9952205
Patient Educ Couns. 2007 Feb;65(2):270-4
pubmed: 17125958
Ann Intern Med. 2000 May 16;132(10):825-32
pubmed: 10819707
Health Aff (Millwood). 2017 Jul 1;36(7):1252-1257
pubmed: 28679812
J Clin Oncol. 2009 Nov 20;27(33):5559-64
pubmed: 19805675
Crit Care Med. 2014 Sep;42(9):1977-82
pubmed: 24810527
Lancet. 2017 Jul 8;390(10090):191-202
pubmed: 28077228
J Clin Oncol. 2008 Aug 10;26(23):3860-6
pubmed: 18688053
JAMA. 1995 Nov 22-29;274(20):1591-8
pubmed: 7474243
JAMA. 2008 Oct 8;300(14):1665-73
pubmed: 18840840
JAMA. 2009 Aug 19;302(7):741-9
pubmed: 19690306

Auteurs

Paul R Duberstein (PR)

Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA; Department of Health Behavior, Society, and Policy, Rutgers University School of Public Heath, Piscataway, New Jersey, USA. Electronic address: paul.duberstein@rutgers.edu.

Richard L Kravitz (RL)

Department of Internal Medicine, University of California, Davis, Sacramento, California, USA; Center for Healthcare Policy and Research, University of California, Davis, Sacramento, California, USA; UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, California, USA.

Joshua J Fenton (JJ)

Center for Healthcare Policy and Research, University of California, Davis, Sacramento, California, USA; UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, California, USA; Department of Family and Community Medicine, University of California, Davis, Sacramento, California, USA.

Guibo Xing (G)

Center for Healthcare Policy and Research, University of California, Davis, Sacramento, California, USA.

Daniel J Tancredi (DJ)

Center for Healthcare Policy and Research, University of California, Davis, Sacramento, California, USA; Department of Pediatrics, University of California, Davis, Sacramento, California, USA.

Michael Hoerger (M)

Tulane Cancer Center, Tulane University, New Orleans, Louisiana, USA; Departments of Psychology, Psychiatry, and Medicine, Tulane University, New Orleans, Louisiana, USA.

Supriya G Mohile (SG)

James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA; Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.

Sally A Norton (SA)

Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA; School of Nursing, University of Rochester, Rochester, New York, USA.

Holly G Prigerson (HG)

Division of Geriatrics and Palliative Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York, USA; Cornell Center for Research on End-of-Life Care, New York, New York, USA.

Ronald M Epstein (RM)

Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA; James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA; Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA; Department of Family Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH